The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high-grade ovarian cancer.

IF 2.5 Q2 OBSTETRICS & GYNECOLOGY Przeglad Menopauzalny Pub Date : 2024-12-01 Epub Date: 2024-12-22 DOI:10.5114/pm.2024.145949

Edyta Leśniak, Emilia Stec-Martyna, Daria Domańska-Senderowska, Hanna Romanowicz, Tomasz Krawczyk, Jan Bieńkiewicz, Andrzej Malinowski, Miłosz Wilczyński

{"title":"The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high-grade ovarian cancer.","authors":"Edyta Leśniak, Emilia Stec-Martyna, Daria Domańska-Senderowska, Hanna Romanowicz, Tomasz Krawczyk, Jan Bieńkiewicz, Andrzej Malinowski, Miłosz Wilczyński","doi":"10.5114/pm.2024.145949","DOIUrl":null,"url":null,"abstract":"Introduction: Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies.Material and methods: Healthy controls and patients with high-grade serous carcinoma (n = 50) were recruited for this study. Samples for testing were obtained from archival paraffin blocks obtained from intraoperative material.Results: The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group (p < 0.05). Higher miRNA 196a expression was also noted in patients with advanced FIGO stages (III, IV). Increased miRNA expression was significantly associated with higher mortality and chemoresistance (p < 0.05). Genotype analysis revealed differing distributions of SNPs (C/C, C/T, T/T) between the study and control groups, but no significant correlation with malignancy was observed.Conclusions: This study supports the critical role of microRNA-196a in the progression of ovarian cancer.","PeriodicalId":55643,"journal":{"name":"Przeglad Menopauzalny","volume":"23 4","pages":"180-184"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726191/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przeglad Menopauzalny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pm.2024.145949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies.

Material and methods: Healthy controls and patients with high-grade serous carcinoma (n = 50) were recruited for this study. Samples for testing were obtained from archival paraffin blocks obtained from intraoperative material.

Results: The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group (p < 0.05). Higher miRNA 196a expression was also noted in patients with advanced FIGO stages (III, IV). Increased miRNA expression was significantly associated with higher mortality and chemoresistance (p < 0.05). Genotype analysis revealed differing distributions of SNPs (C/C, C/T, T/T) between the study and control groups, but no significant correlation with malignancy was observed.

Conclusions: This study supports the critical role of microRNA-196a in the progression of ovarian cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

miRNA-196a及其SNP变体rs11614913在高级别卵巢癌中的临床病理作用

导言卵巢癌是女性死亡的重要原因之一。miRNAs，尤其是miR-196家族，可通过靶向特定通路影响肿瘤进展。材料与方法：本研究招募了健康对照组和高级别浆液性癌患者（n = 50）。检测样本取自术中材料的存档石蜡块：研究发现，与对照组相比，卵巢癌患者的 miRNA 196a 表达明显升高（p < 0.05）。FIGO 晚期（III、IV 期）患者的 miRNA 196a 表达也较高。miRNA 表达的增加与死亡率和化疗耐受性的升高有明显关系（p < 0.05）。基因型分析显示，研究组和对照组的SNPs（C/C、C/T、T/T）分布不同，但未观察到与恶性程度有显著相关性：本研究证实了 microRNA-196a 在卵巢癌进展过程中的关键作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊